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ABSTRACT WALP peptides consist of repeating alanine-leucine sequences of different lengths, ﬂanked with tryptophan
‘‘anchors’’ at each end. They formmembrane-spanninga-helices in lipidmembranes, andmimic protein transmembrane domains.
WALP peptides of increasing length, from 19 to 31 amino acids, were incorporated into N-monomethylated dioleoylphospha-
tidylethanolamine (DOPE-Me) at concentrations up to 0.5mol%peptide.WhenpureDOPE-Me is heated slowly, the lamellar liquid
crystalline (La) phase ﬁrst forms an inverted cubic (QII) phase, and the inverted hexagonal (HII) phase at higher temperatures.
Using time-resolved x-ray diffraction and slow temperature scans (1.5C/h), WALP peptides were shown to decrease the
temperatures of QII and HII phase formation (TQ and TH, respectively) as a function of peptide concentration. The shortest and
longest peptides reducedTQ themost, whereas intermediate lengths hadweaker effects. Theseﬁndings are relevant tomembrane
fusion because the ﬁrst step in the La/QII phase transition is believed to be the formation of fusion pores between pure lipid
membranes. These results imply that physiologically relevant concentrations of these peptides could increase the susceptibility of
biomembrane lipids to fusion through an effect on lipid phase behavior, and may explain one role of the membrane-spanning
domains in the proteins that mediate membrane fusion.
INTRODUCTION
WALP peptides are hydrophobic, a-helical transmembrane
peptides that incorporate into lipid bilayers (1–5). The helical
axes of such peptides are nearly perpendicular to the plane of
the membrane at room temperature (1,3,4,6–8) and the core
of the helices, when membrane-embedded, is strongly
protected from solvent deuterium exchange (9). Because of
these properties, WALP peptides are models for the single
helical membrane-spanning domains found in some integral
membrane proteins (1,4). WALP peptides stabilize inverted
phases in phospholipids in a peptide-length- and concentra-
tion-dependent fashion. In previous studies, peptides whose
lengths as rigid a-helices are short compared to the thickness
of the lamellar phase bilayer of the host lipid were generally
found to be effective in inducing nonlamellar phase forma-
tion, with the concentration required depending on the nature
of the lipids. For example, it was shown that high concen-
trations of short WALP peptides (;10 mol %) can induce
formation of HII and so-called isotropic phases in fully
hydrated phosphatidylcholine systems (1–3), which only
form the lamellar liquid crystalline (La) phase in the absence
of the peptides. Peptide concentrations of 1–4 mol % can
substantially lower the La/HII transition temperature and
induce formation of an inverted cubic (QII) phase in 1,2-
dielaidoyl-sn-3-glycero-3-phosphoethanolamine (DEPE) (10).
WALP concentrations as small as 0.1 mol % substantially
lowered the temperature for isotropic phase formation
in a 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine/1,2-
dioleoyl-sn-glycero-3-phosphoglycerol (DOPE/DOPG) mix-
ture (11). Also, in previous studies, WALP peptides with
lengths longer than the host lipid bilayer thickness were
found to have little or no effect (10,11) on the phase behavior
of the lipids. The fact that WALP peptides and other trans-
membrane peptides (12) can stabilize nonlamellar (HII and
QII) phases is especially interesting in light of the association
of inverted phase behavior with membrane fusion (see, e.g.,
Ellens et al. (13) and Siegel (14)) and the possible inﬂuence
of inverted phase behavior on membrane protein function
(reviewed in Epand (15)).
This work deals with the inﬂuence of WALP peptides on
the formation of QII and HII phases from the La phase in
DOPE-Me. These experiments were motivated by an interest
in the physical chemical mechanisms by which proteins
induce biomembrane fusion, which are still poorly un-
derstood. There is a close relationship between QII phase
formation and the occurrence of membrane fusion in some
pure lipid systems. Simply stated, formation of membrane
fusion pores is postulated to be the ﬁrst step in the La/QII
phase transition (14,16). Membrane fusion rates increase
substantially as unilamellar vesicle dispersions of DOPE-Me
and DOPE/1,2-dioleoyl-sn-glycero-3-phosphocholine lipid
mixtures are incubated at increasing temperatures in the
region where QII phase precursors and QII phases are de-
tected by 31P NMR and freeze-fracture electron microscopy
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(13). The QII precursors are catenoidal connections (inter-
lamellar attachments) with central water channels that form
between lamellae (17–19). These connections, formed be-
tween unilamellar liposomes, would achieve fusion between
the liposomes (nonleaky continuity of both the liposomal
membranes and aqueous contents). Siegel et al. (17,18)
showed that the connections formed in unilamellar liposomal
dispersions in the same temperature region as the observed
increases in membrane fusion rates (13), and that they
formed lattices closely resembling the lattices of catenoidal
intermediates proposed earlier (20) as precursors to QII phase
formation (21). Thus, one can study physical chemical in-
ﬂuences on the fusion rate in model membrane systems
by determining whether given changes in composition or
conditions alter the onset temperature for the La/QII phase
transition (TQ). A number of authors have exploited this
relationship in studying the effects of small peptides and
lipid additives on membrane fusion in DOPE-Me (see, e.g.,
Yeagle et al. (22), Epand and Epand (23), Epand et al. (24),
Nieva et al. (25), Davies et al. (26), and Basa´n˜ez et al. (27)).
DOPE-Me is an appropriate choice of lipid for such studies
because, at slow temperature scan rates (e.g., 1.5C/h), it has
a well characterized La/QII phase transition that begins at
;59.6C (28).
There is increasing evidence that membrane-spanning
domains are important for activity of proteins that mediate
membrane fusion (reviewed in Schroth-Diez et al. (29)).
Moreover, peptides corresponding to the membrane-span-
ning domains of these proteins fuse liposomes in the absence
of other peptides or proteins (30–33). The only domains of
the fusion-mediating protein in inﬂuenza virus that have
been demonstrated to closely associate with the lipids of
target and host membrane lipids under fusogenic conditions
are the so-called fusion peptides and the membrane-spanning
domains of the same protein (34). The interactions of fusion
peptides with lipids have been studied extensively for almost
two decades (35) (for reviews, see Nieva and Agirre (36),
Tamm et al. (37,38), and Martin et al. (39)), whereas bio-
physical characterization of the membrane-spanning do-
mains of fusion proteins and their activity in liposome fusion
started more recently (30–33,40).
In this study, we used time-resolved x-ray diffraction
(TRXRD (41)) to determine the changes in lipid phase be-
havior (and especially changes in TQ) induced by adding
WALP peptides to DOPE-Me. By using TRXRD and a host
lipid with a well deﬁned TQ (28), we can determine the
effects of different peptides on QII phase formation with
greater precision than in previous studies (see, e.g., van der
Wel et al. (10), Morein et al. (11), and Liu et al. (12)). Also,
TRXRD directly veriﬁes the presence of QII phases, whereas
other methods, such as 31P NMR, cannot distinguish be-
tween QII phases and QII phase precursors. In light of recent
theoretical work (16), the results allow us to estimate the
effects that such membrane-spanning peptides have on the
stability of fusion pores. It can be shown (16) that 1 mol % of
a particular WALP peptide would lower the energy of fusion




Buffers and reagents were as described in Cherezov et al. (28).
WALP peptide synthesis
Table 1 shows the sequences of the peptides used in this study. The peptides
were prepared by ﬂuorenylmethoxycarbonyl (Fmoc) solid-phase methods
on an ABI 433A peptide synthesizer (PE Biosystems, Foster City, CA). The
Fmoc amino acids, from Advanced ChemTech (Louisville, KY) or Bachem
Bioscience (King of Prussia, PA), were coupled as hydroxybenzotriazol esters
in the presence of [2-(1 H-benzotriazol-1-yl)-1,1,2,3-tetramethyluronium
hexaﬂuorophosphate] to a preloaded Fmoc-L-Ala Wang resin (Advanced
ChemTech). All peptide synthesizer reagents were purchased from PE
Biosystems except dichloromethane and N-methylpyrrolidinone, which
were high-performance liquid chromatography (HPLC)-grade obtained
from Allied Signal (Muskegon, MI). Occasional failure sequences, due
to incomplete coupling of a particular hydrophobic amino acid, were capped
using acetic anhydride; this precaution was important to prevent the ac-
cumulation of signiﬁcant amounts of (n-1) or (n-2) peptides. Fmoc-
deprotection at each step was with piperidine/N-methylpyrrolidinone
(1:4 v/v). The synthesis was completed by coupling acetyl-Gly (Advanced
ChemTech), also as the hydroxybenzotriazol ester. The completed peptides
were cleaved from the resin with 20 vol % distilled ethanolamine (Aldrich
Chemical, Milwaukee, WI) in dichloromethane for 48 h at 25C (42). The
peptides were lyophilized to a white powder from triﬂuoroethanol (TFE)/
water (1:1 v/v). Based on analytical HPLC, the purity of the peptides was
80–95%.
Some batches of WALP 19, 23, 27, and 31 were further puriﬁed via
reversed-phase HPLC. These will be referred to as puriﬁed peptides.
Samples of WALP19, WALP23, and WALP27 were dissolved in TFE (50
mg/mL) and puriﬁed on a Zorbax SB-C8 semipreparative column using
a solvent gradient of methanol and 0.1 vol % triﬂuoracetic acid in deionized
water. After puriﬁcation, the peptides were lyophilized to a white powder
from TFE/deionized water (50:50 v/v) as described above, and their purity
was estimated to be 98% by analytical reversed-phase HPLC analysis and
electrospray mass spectral analysis. Due to its length, WALP31 was HPLC-
puriﬁed using a Nucleosil column (SI 100-10, pore size 100 A˚), obtained
from Macherey-Nagel (Du¨ren, Germany) with chloroform/methanol/water
(80:19:1 v/v) as eluent, and then lyophilized to a white powder,;98% pure.
HPLC puriﬁcation of these very hydrophobic peptides results in a large
peptide loss, presumably because of aggregate formation.
TABLE 1 Sequences and lengths of the WALP peptides used
Peptide Sequence Length as an a-helix (A˚)*
WALP19 Ac-GWW-(LA)6 L-WWA-e 28.5
WALP23 Ac-GWW-(LA)8 L-WWA-e 34.5
WALP25 Ac-GWW-(LA)9 L-WWA-e 37.5
WALP27 Ac-GWW-(LA)10 L-WWA-e 40.5
WALP31 Ac-GWW-(LA)12 L-WWA-e 46.5
Ac, acetyl; e, ethanolamine; A, alanine; G, glycine; L, leucine; and W,
tryptophan.
*The helix length was calculated by multiplying the number of residues by
1.5 A˚.
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DOPE-Me
N-monomethylated 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE-
Me) was used as received from Avanti Polar Lipids (Alabaster, AL), as
lyophilized powder. All the DOPE-Me used in this study was from the same
lot that was used in studies of the La/QII transition in pure DOPE-Me (28).
Lipid received from the manufacturer was stored at 70C until samples
were prepared for x-ray diffraction experiments.
Methods
DOPE-Me/peptide samples
Peptides were mixed with DOPE-Me using a TFE/water lyophilization
technique developed previously (1). WALP peptide stock solutions (0.3–3.4
mg/mL, depending on the peptide and the desired concentration in the lipid)
were made up in TFE. The WALP peptide concentration in the TFE stock
solution was determined by the absorbance after dilution with methanol
(ﬁnal methanol concentration .95% v/v) at 280 nm, using blank solutions
of the same TFE/methanol ratio. The molar extinction coefﬁcient of
N-tertiary butyloxycarbonyl L-tryptophan at 280 nm was determined in
methanol as 5590 M1 cm1 (data not shown). Since there are four tryp-
tophan residues in each WALP peptide, we used a molar extinction coef-
ﬁcient of 22,400 M1 cm1 for all the peptides. An appropriate amount of
lyophilized DOPE-Me as received from the supplier was weighed into a
Pyrex ﬂask and hydrated with 0.25 mL of Milli-Q water by vortex mixing. A
0.25-mL of WALP peptide stock solution of appropriate concentration in
TFE was added to the hydrated DOPE-Me with vortex mixing, diluted with
3.75 mL of water with vortex mixing on ice, frozen in liquid nitrogen, and
then lyophilized. Lyophilized samples were hydrated in 150 mM NaCl,
20 mM N-tris[Hydroxymethyl]methyl-2-aminoethane-sulfonic acid, 0.1
mM EDTA, pH 7.4, by vortex mixing under Ar and equilibrating on ice
for 1 h, after which they were subjected to six freeze/thaw cycles (dry ice/
room temperature water). Peptide concentrations are given in units of mol %
(100 3 moles of peptide/(moles of peptide 1 moles of DOPE-Me)). The
error in peptide concentration in each sample is estimated to be 65%.
X-ray diffraction samples
Samples were prepared as described previously (28). Capillaries were stored
in closed, screw-capped test tubes at 70C until they were used (generally
less than two weeks). Values of TQ obtained on single sets of samples
observed after different times of storage at 70C were the same to within
the reproducibility of the measurement (1C) for samples stored for at least
35 days. Values of TQ determined by rotating anode x-ray diffraction ex-
periments with samples made using different preparations of the same
WALP peptide were the same to within 2C after storage times of 1–35 days.
Rotating anode and synchrotron source x-ray
diffraction measurements
These measurements were performed using the same apparatus and methods
described in detail in (28), with the following exceptions. In the synchrotron-
source experiments, a monochromatic x-ray beam of either 8.979 keV
(wavelength 1.38 A˚) or 8.045 keV (wavelength 1.54 A˚) was focused at
a detector position of 125.5 cm (8.979 keV) or 112.0 cm (8.045 keV), as was
determined using a silver behenate standard (43). The temperature in the
sample cell was determined using thermocouples inserted into sample
capillaries, and was correct to within 0.2C versus NBS-traceable standards
(28). Samples were incubated for 1 h at the starting temperature before any
of the experiments commenced. During temperature-scan experiments
diffraction patterns were collected using 1-min exposures and at 8-min
intervals, at a scan rate of 1.5C/h. These correspond to intervals of 0.2C,
and to changes in temperature of 0.025C during each exposure. One data set
(0.5 mol % WALP27 in DOPE-Me) was obtained at a scan rate of 2C/h,
with 1-min exposures every 7.5 min (exposures at intervals of 0.25C). All
temperature-scan experiments were performed in the heating direction. The
temperature range examined for all peptides extended to 12C above TQ. In
temperature-jump experiments, twenty 1-min exposures were collected in
succession, followed by eight 1-min exposures at intervals of 5 min and
three or more 1-min exposures at intervals of 10 min. The x-ray shutter was
closed during the idle time between exposures to minimize radiation damage
(28,44,45).
Radiation damage study
A radiation damage study protocol very similar to that described for
experiments with pure DOPE-Me (28) was followed. Using NSLS
beamline X-12B (8.979 keV), we exposed a capillary containing 0.5 mol %
WALP31 in DOPE-Me continuously for 1 h at 35C. This temperature is
;3C below the temperature at which QII phases ﬁrst formed from the La
phase in a sample of the same preparation, as determined from a previous
rotating anode temperature-scan experiment. As with the sample of pure
DOPE-Me treated in the same way at 57C (28), 60 successive 1-min
exposures were made while the sample was in the x-ray beam, and patterns
obtained during this time showed the presence of only lamellar phase.
Immediately after the 60-min irradiation, 1-min exposures were used to
collect diffraction patterns from adjacent, unirradiated regions of the same
sample. As with the pure DOPE-Me sample (28), the intensity of the
lamellar phase diffraction peaks decreased with time throughout the
irradiation, and decreased slightly in the displaced patterns (obtained 12–
20 min after the end of the experiment) versus the ﬁnal pattern obtained
during the 60-min irradiation. As discussed in Cherezov et al. (28), this
continuous decrease also occurs in DOPE-Me samples irradiated only
intermittently and DOPE-Me samples examined with much weaker rotating-
anode x-ray sources (see, e.g., Gruner et al. (46)). Since the QII phase was
not observed in the 0.5 mol % WALP31 sample irradiated for 60 min, we
conclude that the radiation doses used in these experiments had no effect or




Previously, we showed that, when heated at a scan rate of
1.5C/h, DOPE-Me forms a QII phase starting at 59.6 6
0.6C, and then the HII phase (to coexist with the QII phase)
starting at 63.7 6 0.4C (28). The inclusion of WALP
peptides alters these temperatures. An example of syn-
chrotron TRXRD data is given in Fig. 1, which shows
a diffraction pattern obtained with 0.2 mol % WALP19 in
DOPE-Me at 53C. It was collected as part of a series as
the sample was heated from 44.7 to 54.9C at 1.5C/h. This
pattern was chosen because it shows the simultaneous
presence of diffraction rings from the QII-Pn3m, HII, and La
phases during a series of phase transitions from the lamellar
phase. WALP-containing samples were examined using
slow temperature scans because the La/QII phase transition
in pure DOPE-Me is very slow (hours) and hysteretic
(21,28). A direct La/QII phase transition is detected in pure
DOPE-Me only when the temperature scan rate is ,3C/h,
and the observed transition temperature is nearly constant
with decreasing scan rate at #1.5C/h (28). Therefore, we
used a scan rate of 1.5C/h in our rotating-anode and
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synchrotron experiments to avoid possible ambiguities in
phase behavior. Formally, for the QII phases noted as QII-Pn3m
in this work, we cannot distinguish between the space groups
Pn3m and Pn3 (47). Harper et al. state that these cannot be
distinguished on the basis of powder patterns alone (48).
Transition temperatures as determined by
TRXRD experiments
TQ and TH are the onset temperatures for formation of the
QII and HII phases, respectively. Lamellar and nonlamellar
phases coexisted over temperature intervals of between 3
and 10. Fig. 2 summarizes the rotating-anode TRXRD
transition temperature data on WALP/DOPE-Me systems.
The plots in Fig. 2 show the dependence of TQ and TH on the
concentration of WALP peptide for four peptides: WALP19,
WALP23, WALP27, and WALP31. As for pure DOPE-Me
(28), TQ was determined as the temperature at which the ﬁrst
low-angle reﬂections (corresponding to spacings of;220 A˚)
appeared. The presence of QII phases under these condi-
tions was veriﬁed by synchrotron source temperature scan-
experiments, which will be discussed below. For different
capillaries made from the same WALP/DOPE-Me sample,
the reproducibility of TQ as determined from rotating anode
streak-camera images was generally to within 61C. For
capillaries made from different samples of the same WALP
peptide, the reproducibility was 62.5C or less. Therefore
different samples of the same peptide had the same efﬁcacy
in lowering TQ to within the error of the measurements.
The data in Fig. 2 show that all the WALP peptides lower
TQ and TH, which for the pure lipid under these conditions
are 59.6 6 0.6C and 63.7 6 0.4C, respectively (28). Both
TQ and TH decrease linearly with increasing peptide concen-
tration over most of the concentration range. The extent of
the effects on TQ and TH depends on the length of the WALP
peptide.
The slopes of the plots of TQ versus peptide concentra-
tion are 45C/mol %, 22C/mol %, 13C/mol %, and
34C/mol % for WALP19, WALP23, WALP27, and
WALP31, respectively. This shows that the shortest (WALP19)
and longest (WALP31) peptides are most effective in re-
ducing TQ, whereas the intermediate-length peptides have
more modest effects. Measurements of TQ were also made
for samples containing 0.5 mol % of the peptide WALP25.
From these measurements, a value of TQ of 53.6 6 1.3C
(average of four determinations) was determined. The peptide-
length-dependent effects on TQ evaluated at 0.5-mol %
peptide concentration are summarized in Fig. 3. The data for
the pure hydrated DOPE-Me represents the average of six
trials (59.6C 6 0.6C).
In control experiments using 0.5 mol % of puriﬁed
WALP19, WALP23, WALP27, and WALP31 (Fig. 3), the
puriﬁed peptides (open circles) lowered the TQ of DOPE-Me
FIGURE 1 Typical two-dimensional detector image of a diffraction
pattern from 0.2 mol % WALP19 in DOPE-Me at 53C recorded using
synchrotron radiation. This pattern was obtained in a 1-min exposure as
described in Cherezov et al. (28), as part of a series as the sample was heated
from 44.7C to 54.9C at a scan rate of 1.5C/h. This pattern shows the
presence of diffraction rings from QII-(Pn3m), HII, and La phases, as labeled
in the ﬁgure. The QII-Pn3m (110) reﬂection and La (002) reﬂections are at
174 A˚ and 31.1 A˚, respectively.
FIGURE 2 Effects of WALP peptides on the onset temperatures for
formation of QII (TQ) and HII phases (TH) in DOPE-Me as a function of
peptide length and concentration, as determined via rotating-anode TRXRD
experiments. The lines in the plots are linear regression ﬁts to the data. The
correlation coefﬁcients for the plots of TQ and TH, respectively, are (A) 0.954
and 0.944; (B) 0.887 and 0.911; (C) 0.791 and 0.883; and (D) 0.925 and
0.991. The ﬁts included the data at zero concentration. The TQ value at zero
peptide concentration (59.6 6 0.6C; pure DOPE-Me) represented six
measurements. In the case of WALP31, the intercept of the TQ line with the
temperature axis is 4.8C below TQ for pure DOPE-Me.
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with qualitatively similar length dependence as the non-
puriﬁed peptides (solid circles). However, the extent of re-
duction in TQ for each WALP length was smaller for the
puriﬁed peptides, in particular for the shortest and longest
peptides.
The effects of the peptides on TH were rather similar to
those on TQ. The slopes of the plots of TH versus peptide
concentration are 64C/mol %, 29C/mol %, 8C/mol
%, and 36C/mol % for WALP19, WALP23, WALP27,
and WALP31, respectively, showing that the shortest
(WALP19) and longest (WALP31) peptides are most ef-
fective in reducing TH. For samples containing 0.5 mol % of
WALP25, TH was found to be 58.26 0.3C. Thus, WALP25
only has a small effect on TH, rather similar to that of
WALP27.
At relatively high peptide concentrations of 0.5 mol %, HII
phases were observed only for WALP27 and WALP25, at
;5C above TQ (Fig. 2 C). Pure DOPE-Me forms the HII
phase at ;4C above TQ when examined in similar slow
temperature-scan heating experiments. Thus, WALP25 and
WALP27 perturb the phase behavior of DOPE-Me less than
the other WALP peptides.
Synchrotron source temperature-scan experiments were
performed on eight of the WALP/DOPE-Me compositions,
to reﬁne the measurements of TQ, determine which QII
phases formed, and study the behavior of the QII phase lattice
constants with temperature and time after temperature jumps.
An example of the synchrotron TRXRD data on QII phase
formation is shown in Fig. 4 A, for 0.5 mol % WALP31 in
DOPE-Me. In this experiment, the sample was heated
continuously from 35.0C to 39.0C, at 1.5C/h. The only
peaks in the 35.0C pattern correspond to the ﬁrst- and
FIGURE 3 Summary of the effects of WALP peptides on TQ as a function
of WALP peptide sequence length. The plot shows the extent of reduction in
TQ at a peptide concentration of 0.5 mol % for each WALP peptide
examined in this study. The data are plotted in this fashion to facilitate
comparison of the puriﬁed WALP peptides and WALP25, which were
studied only at a concentration of 0.5 mol %, with the data for the peptides in
Fig. 2. (d) Nonpuriﬁed peptides. (s) Puriﬁed peptides.
FIGURE 4 Results of synchrotron temperature-scan experiments using
0.5 mol % WALP31 in DOPE-Me, showing formation of QII phases. The
curves are the radial integrals of two-dimensional diffraction patterns like
the one in Fig. 1, taken at temperature intervals of 0.2C. The ordinate is the
diffracted intensity, and the abcissa is the magnitude of the scattering vector
q ¼ 2p/d, where d is the interplane spacing in A˚. (A) Diffraction patterns
from an experiment in which the temperature was increased continuously at
1.5C/h, from 35.0C to 39.0C. The only peaks in the 35.0C pattern are the
indicated reﬂections from the La phase. At 37.0C, two peaks appear at
q ¼;0.032 and 0.038 A˚1 (arrowheads). At 37.4C, two more small peaks
appear at;0.057 A˚1 and 0.069 A˚1 (arrowheads). In the pattern at 37.6C,
the four new peaks are labeled as the indicated reﬂections from a QII-Pn3m
phase. (B) Diffraction patterns obtained from another sample of 0.5 mol %
WALP31 in DOPE-Me, heated at 1.5C/h between 37.0C and 42.1C. The
pattern at 40.2C shows the same QII-Pn3m and La phase reﬂections as the
37.6C pattern in A. A new peak at q ¼ 0.042 A˚1 became clearly visible in
the 41.3C data (arrowhead). In the pattern at 42.1C, this peak had grown
in intensity at the expense of the QII-Pn3m reﬂections. The plot at the top of
the ﬁgure was obtained 15 min after the end of the scan, with the temperature
constant at 42.1C. Additional peaks are visible in this pattern (arrowheads).
The two peaks indicated by arrows index as the ﬁrst two (211 and 220)
reﬂections of a QII-Ia3d phase. The higher-q peaks likely correspond to the
superposition of multiple reﬂections, and could not be reliably indexed.
Dashed arrow in A: the very small feature in the baseline at q¼ 0.159 A˚1 is
due to a ﬂaw in the detector, and does not represent a diffraction peak.
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second-order reﬂections from the La phase, at q¼ 0.100 A˚1
and 0.201 A˚1 (62.8 and 31.3 A˚), respectively. At 36.8C,
a broad peak appeared at q¼ 0.028–0.04 A˚1. This resolved
into two peaks at q¼;0.032 A˚1 and 0.038 A˚1 (d¼;196
and 165 A˚) at 37.0C (Fig. 4 A, arrowheads). These two
peaks are at q values in approximately the correct ratio to
correspond to the 110 and 111 reﬂections from a QII-Pn3m
lattice. At 37.6C, two additional broad peaks became
discernible at q ¼ ;0.057 A˚1 and 0.069 A˚1 (d ¼ ;110
and 91 A˚). Although of low intensity, these two peaks
persisted up to the end of the scan at 39.0C (data not
shown). The same two peaks were also observed in a second
temperature scan on a sample of the same composition (Fig.
4 B; see below) starting at 38.0C (data not shown). The set
of four peaks visible at 37.6C index as the 110, 111, 211,
and 221 reﬂections from a QII-Pn3m phase. To the eye, this
series is missing the 200 and 220 reﬂections, but these are
usually weak in diffraction patterns from QII phases of
DOPE-Me (21,28). Peak-ﬁtting procedures identiﬁed the
weak d220 reﬂection. These ﬁve reﬂections yielded a QII-
Pn3m lattice constant of 282 6 3 A˚ at 37.6C. A rotating
anode diffraction pattern obtained at 39C from a sample of
the same composition also detected a QII-Pn3m phase (data
not shown). In all peptide-free and WALP-containing
samples of DOPE-Me examined via synchrotron-source
TRXRD, the ﬁrst QII phase to form was always QII-Pn3m.
The ﬁrst evidence of QII phase formation in temperature-scan
experiments was the appearance of the 110 and 111 peaks,
as in the 37.0C frame of Fig. 4 A. We deﬁned TQ in the
synchrotron source data as the temperature at which these
reﬂections were ﬁrst obviously resolved by eye, i.e., without
the use of peak-ﬁtting procedures. In practice, background
subtraction and peak-ﬁtting procedures could often identify
traces of QII phase diffraction at temperatures several tenths
of a degree below the tabulated values of TQ.
The values of TQ as determined via synchrotron-source
and rotating anode TRXRD experiments are compared in
Table 2. The values of TQ from the two methods generally
agree with each other to within 0.2–2.4. The TQ values for
WALP19, WALP23, and WALP25 determined via this
method are .2.4 lower than determined with the rotating
anode apparatus. This is probably due to the greater sensi-
tivity of the detector used at the synchrotron facility.
Formation of QII-Ia3d phase in
WALP/DOPE-Me systems
Synchrotron experiments showed that a second type of QII
phase, the QII-Ia3d phase, formed in addition to the QII-
Pn3m phase in ﬁve compositions (Table 2). An example is
given in Fig. 4 B, which shows diffraction patterns obtained
at 0.5 mol % of WALP31 as it was ramped from 37.0 to
42.1C at 1.5C/h. The diffraction pattern obtained at 40.2C
shows the same four Pn3m reﬂections as in Fig. 4 A. At
temperatures between ;40 and 41C, there was an increase
in diffracted intensity between the 110 and 111 reﬂections of
the QII-Pn3m diffraction pattern. This resolved into a new
peak at q ¼ 0.0427 A˚1 (160 A˚), which became obvious at
41.3C (arrowhead). The peak grew in intensity at higher
temperatures, at the expense of the QII-Pn3m peaks. A peak
at q ¼ 0.0503 A˚1 (125 A˚) was also resolved in a pattern
obtained 15 min after the end of the scan at 42.1C. These
two peaks are indicated by arrows, and index as the ﬁrst two
reﬂections (211 and 220) expected for a QII-Ia3d phase with
a lattice constant of 354 A˚. In the same pattern, there are new
peaks at q ¼ 0.086 A˚1 and 0.127 A˚1 (arrowheads). These
peaks are too broad and contain too many candidate reﬂec-
tions to be accurately indexed. The peak at q ¼ 0.086 A˚1
may be a combination of the 332 reﬂection of the QII-Ia3d
phase and reﬂections from the residual QII-Pn3m phase. The







Phases present at ﬁnal temperature
in synchrotron-source experiment
z
Synchrotron (C)*y Rotating-anode, (C)*
Control 0 59.4 59.7 61.9 La/QII-Pn3m
0 58.0 58.2 61.0 La/QII-Pn3m
WALP19 0.2 ,44.7 47.1 54.9 La/QII-Pn3m/QII-Ia3d/HII
0.5 ,33.0 34.8 42.6 La/QII-Ia3d/(HII)
WALP23 0.5 ,45.2 47.4 53.4 La/QII-Ia3d/(HII)
WALP25 0.5 ,49.6 52.0 59.8 La/QII-Pn3m/QII-Ia3d/HII
WALP27 0.2 ,54.0 54.2 62.8 QII-Pn3m/QII-Im3m/HII
0.5 53.2 52.6 59.7 QII-Pn3m/HII
WALP31 0.5 37.0 37.8 39.0 La/QII-Pn3m/QII-Ia3d
0.5 38.0 37.8 42.0 La/QII-Pn3m/QII-Ia3d
*TQ measurements by both synchrotron and rotating-anode techniques were performed on samples from the same preparations, to remove the effect of
preparation-to-preparation variability (see Materials and Methods). All measurements were made at a temperature scan rate of 1.5C/h, except for the
synchrotron experiment on 0.2 mol % WALP19, which was made at 2C/h.
y, signiﬁes that some QII phase was present at the start of the temperature scan, which began at the temperature indicated.
zThe brackets in (HII) signify that small amounts of HII phase were detected at the ﬁnal temperature in the synchrotron experiments that did not appear in the
corresponding rotating-anode experiments.
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peak at q ¼ 0.127 A˚1 may represent high-order reﬂections
from the QII-Ia3d phase.
In Fig. 4 B, the two reﬂections at q ¼ 0.042 A˚1 and 0.05
A˚1 (observed at temperatures$41.3C and 42.1C, respec-
tively) are too weak and too few in number to rigorously
identify the new lattice. However, we tentatively identify this
higher-temperature QII lattice as the QII-Ia3d phase, based on
the ratio of the apparent QII-Pn3m and QII-Ia3d lattice
constants. Fig. 5 A shows plots of the lattice constants of the
two QII phases as a function of temperature for the experi-
ment in Fig. 4 B. Fig. 5 B shows that the ratio of the QII-Ia3d
and QII-Pn3m lattice constants over the entire temperature
range is centered at 1.54, close to the value of 1.58 expected
for coexisting QII-Ia3d and QII-Pn3m lattices (49,50). The
putative QII-Ia3d phases were observed in synchrotron
experiments at temperatures between 2 and 9C above TQ
in the WALP peptide systems (Table 2). The diffracted
intensity from this phase grew at the expense of diffraction
from the QII-Pn3m phase with increasing temperature.
QII-Ia3d phase formation is sensitive to the temperature
history of the sample. The QII-Ia3d phase did not always
appear in temperature-jump experiments using samples of
the same composition that would form QII-Ia3d phase in
temperature-scan experiments. The samples subjected to
temperature-jump experiments were 0.5 mol % WALP19,
0.5mol%WALP23, and 0.5mol%WALP31 (data not shown).
We do not know the reasons for this difference between
temperature-scan and temperature-jump experiments.
DISCUSSION
Reduction in TQ and TH in DOPE-Me by
WALP peptides
The principal result of this study is that WALP peptides
substantially lower the temperatures at which QII and HII
phases form in DOPE-Me in a peptide-length-dependent
manner (Figs. 2 and 3). For most peptides, the extent of the
decrease in TQ and TH is linear in peptide concentration
(Fig. 2). At constant peptide concentration, the extent to which
each peptide reduces TQ and TH depends on the peptide
length. This peptide length dependence is biphasic (Fig. 3):
both the shortest (WALP19) and longest (WALP31) pep-
tides were most effective in reducing the transition temper-
atures, compared to the peptides of intermediate lengths.
Qualitatively, the phase behavior of WALP/DOPE-Me sys-
tems in temperature-scan experiments resembles that of pure
DOPE-Me (28), where the QII phase forms at a lower tem-
perature than the HII phase, and QII-Pn3m is the ﬁrst QII
phase to appear.
Comparison with other studies of WALP effects
on nonlamellar phase formation
Two recent studies investigated the effects of WALP pep-
tides on nonlamellar phase transition temperatures in DOPE/
DOPG (11) and in DEPE (10). In both reports, QII phase
formation was monitored primarily by observation of iso-
tropic 31P NMR resonances, with x-ray diffraction used to
demonstrate formation of the QII phase under selected
conditions. It should be noted that isotropic 31P NMR res-
onances can arise from interlamellar attachments 10–15
below TQ in lipids such as DOPE-Me (e.g., for DOPE-Me,
TI in Ellens et al. (13) versus TQ in Cherezov et al. (28)).
Most of our results are consistent with those of Morein
et al. (11) and van der Wel et al. (10). First, WALP peptides
lower the temperatures at which isotropic resonances are
observed in each lipid system. Second, both van derWel et al.
and Morein et al. found that in the series WALP19–
WALP31, shorter peptides were more effective than longer
peptides in inducing formation of the isotropic phase. We
found that the shorter peptides in the series WALP19–
WALP25 reduced TQ to a greater extent than did longer ones
(Figs. 2 and 3). Third, van der Wel et al. (10) found that the
shortest WALP peptides (WALP14 to WALP19) lowered
the TH of DEPE, whereas WALP21 and WALP23 had
FIGURE 5 Lattice constants and lattice constant ratio of the QII phases
detected by the synchrotron TRXRD experiment in Fig. 4, as a function of
temperature, for 0.5 mol % WALP31 in DOPE-Me. (A) Dependence of the
lattice constants of the QII-Pn3m and QII-Ia3d phases on temperature. (B)
Dependence of the ratio of the QII-Ia3d and QII-Pn3m lattice constants on
temperature. This ratio is close to the value of 1.58 expected for coexisting
QII-Ia3d and QII-Pn3m lattices (49,50).
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smaller or vanishing effects. In qualitative agreement with
this, we found that the shortest peptide (WALP19) was most
effective in reducing TH (Fig. 2). Finally, van der Wel et al.
(10) found that 2 mol % of different-length WALP peptides
had only a small effect (;1 A˚ or less) on the HII tube diam-
eter in DEPE at 60C. We found that the peptides had even
smaller effects (,0.2 A˚) on lattice dimensions in DOPE-Me
at a concentration of 0.5 mol % (data not shown).
Nevertheless, there is one important difference in our
results. In DOPE-Me, we observed that WALP31 reduced
TQ to a signiﬁcant extent. In contrast, in the studies by van
der Wel and colleagues (10) and Morein et al. (11) it was
found that WALP31 was less effective than shorter WALP
peptides in inducing isotropic phase, perhaps due to a ten-
dency of WALP31 to aggregate and phase-separate. In
DOPE-Me, WALP31 does not phase-separate at concen-
trations up to 0.5 mol %; rather, it reduces TQ to an extent
that is nearly linear in peptide concentration in the range
0.05–0.5 mol % (Fig. 3D). Nevertheless, our data do suggest
that WALP31 also has a tendency to oligomerize. The plot of
TQ versus WALP31 concentration (Fig. 3 D) has a sub-
stantially larger apparent slope at concentrations ,0.05 mol
% than at higher concentrations. (We note a similar although
less severe trend for WALP19 in Fig. 2 A.) Thus, at concen-
trations ,0.05 mol % WALP31 appears to be present in a
form that is more effective in reducing TQ on a mole-for-mole
basis than at higher concentrations. This suggests that at
concentrations .0.05 mol % WALP31 shows a higher ten-
dency than shorter analogs to form dimers or small aggregates.
A likely explanation for thepeptide-lengthdependenceof the
phase behavior is that WALP peptides that are too long or too
short to ﬁt into the bilayer will disturb lipid packing in DOPE-
Me in different ways, but with a similar result at relatively
low peptide concentrations: a lowering of both TQ and TH.
In the case of the longer WALP31, the extent to which the
system reacts by forming small aggregates of the peptide and
cubic phases (as in DOPE-Me), versus more extensive ag-
gregation and phase separation of the peptide (as in DEPE
and PE/PG), seems to be very sensitive to the details of the
particular system. The extent of hydrophobic mismatch
should be comparable for a given WALP peptide in DOPE-
Me (La phase bilayer thickness of 39 6 5 A˚; (46)), DOPE,
DEPE, and DOPE/DOPG. It is therefore more likely that the
differences in phase behavior of WALP31 in DOPE-Me as
compared to the previous observations in DEPE and PE/PG
are related to differences in the packing properties of the
lipids in these systems. Since lipid packing is very different
in the QII and HII phases than in the La phase, it is interesting
that TQ and TH are affected in the same way and to nearly the
same extent by each peptide (Fig. 2). It may be that the
peptides raise the free energy of the peptide-lipid La phase
with respect to the pure lipid La phase more than they affect
the free energy of the two inverted phases. This would have
the effect of decreasing both TH and TQ in parallel as
a function of peptide length, as is observed.
This explanation rationalizes most, but not all, of the data.
Although TH and TQ are reduced by similar extents for all the
peptides, the data in Fig. 2 show that HII phase exists for
different peptide concentration ranges for different WALP
peptides. HII phase is observed through 0.5 mol % for
WALP27, but only through 0.2 mol % for WALP19 and
WALP23, and only up until 0.05 mol % for WALP31. This
could be due to nonequilibrium effects of the peptides on
transition kinetics. However, different peptides may also be
affecting the relative stability of QII and HII phases differ-
ently. It has been pointed out that peptides could affect QII
phase stability more than HII phase stability if they change
the monolayer Gaussian curvature elastic modulus of the
lipids, k (16,51). Different-length peptides are expected to
affect k differently, since this modulus is sensitive to the
distribution of mass and intermolecular forces at different
depths within the bilayer (52), and small changes in k have
a big inﬂuence on TQ (16). Further studies of the effects of
peptides on inverted phase stability (and especially on QII
phase stability) are required to settle this question.
It has been suggested that membrane-spanning peptides
could change TH by effects on hydrophobic interstices (1)
and TQ by stabilization of differences in membrane thickness
within the unit cells of the inverted phases (53). Interstice
stabilization cannot explain the observed effects on TQ. QII
phases consist of continuous bilayers, with no hydrophobic
interstices, so peptides cannot lower TQ by packing inter-
stices. More recent theoretical work (54,55) indicates that the
chain-stretching energy associated with the bilayer thickness
gradient in the QII phase is negligible for QII phases with unit
cells as large as those observed in this study. The difference
in free energy with respect to the La phase is due to a dif-
ference in bending elastic and Gaussian curvature energy
(54,55). Thus the WALP peptides do not change TQ via an
effect on the chain-stretching energy of the QII phase.
It is likely that WALP peptides change TH by stabilizing
gradients in monolayer thickness in the HII phases (1). These
gradients are imposed by the necessity of ﬁlling hydrophobic
interstices between HII tubes. As discussed in Killian et al.
(1), this could explain the effects of WALP peptides on TH
for peptides that are shorter than the La phase bilayer
thickness (WALP19, WALP23, andWALP25 in this system).
It is not clear that this principle explains the effects of
peptides that have helices longer than the La phase bilayer
thickness (WALP27 and WALP31). If membrane-spanning
peptides form rigid rods, they must exist only in the regions
of the HII unit cell where the monolayers are opposed back-
to-back, so that the two hydrophilic end groups of the peptide
each reside in a lipid-water interface. These bilayer-like
regions of the HII phase are thinner than the bilayers in the La
phase bilayer from which the HII phase forms. Thus, there
would be an increased extent of peptide-lipid length mis-
match in the HII versus the La phase for peptides like
WALP27 and WALP31. This would increase TH, rather than
lower it, as we observed (Fig. 3, C and D). However, such
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‘‘long’’ membrane-spanning peptides might be able to lower
TH by ﬁlling hydrophobic interstices directly, if they can
form kinks or bends. If the end groups of the peptide have to
be in lipid-water interfaces, simple geometry shows that the
peptide can ﬁll an interstice if it can bend or kink in the
middle by ;30. This might explain the efﬁcacy of ‘‘long’’
peptides in reducing TH. Interestingly, in peptides mimicking
the membrane-spanning domains of some fusion-mediating
proteins, activity in fusing pure lipid vesicles is correlated
with increasing conformational ﬂexibility of the peptides
(30–33). Membrane fusion intermediates contain hydropho-
bic interstices (14,56). It may be that the more ﬂexible
peptides have the ability to form kinks, and act in part by
ﬁlling the hydrophobic interstices within fusion intermedi-
ates in an analogous manner.
In addition to WALP peptides, other length-mismatched,
transmembrane peptides can also inﬂuence lipid phase
behavior. Recently, Liu et al. (12) studied the effects of
peptides with polyleucine membrane-spanning domains and
positively charged ﬂanking residues on the TH of DEPE and
dipalmitelaidoylphosphatidylethanolamine, and inferred the
presence of QII phases from
31P NMR data. In these ex-
periments, transmembrane peptides longer than the PE
membrane thickness also lowered TH more than peptides
with lengths approximately the same as the lipid mem-
brane thickness. The results are very similar to our results
comparing the effects of WALP31 versus shorter analogs on
TH and TQ.
Implications for protein-mediated membrane
fusion: inﬂuence of transmembrane domains
Proximity of biomembrane systems to the
lamellar/nonlamellar phase boundary
Many biomembranes or biomembrane lipid extracts form
nonlamellar phases if incubated above the physiological
temperature (see, e.g., de Grip et al. (57), Burnell et al. (58),
Gounaris et al. (59), Ranck et al. (60), Quinn et al. (61), and
Lindblom et al. (62)), if dehydrated (see, e.g., Gruner et al.
(63), Crowe and Crowe (65), and Gordon-Kamm and
Steponkus (65)), or if treated with divalent cations (see,
e.g., Cullis et al. (66), Albert et al. (67), Nicolay et al. (68),
and Killian et al. (69)). Furthermore, the fusion rate in
several lipid systems accelerates as one approaches the
La/QII phase boundary, and the intermediates in membrane
fusion correspond to intermediates in this phase transition. In
some lipid extracts, QII phases or QII phase precursors are
observed (62). More generally, QII phases should be stable
in phospholipids in a broad temperature interval below
TH, although QII phase formation can be slowed or inhib-
ited in some cases (14). QII phases even form in mixtures
of unsaturated acyl-chain PC and cholesterol; two plasma
membrane lipid components that cannot form inverted
phases in excess water by themselves ((70,71); B. Tenchov,
R. C. MacDonald, and D. P. Siegel, unpublished). Under
physiological conditions, the lipids of many biomembranes
may be near the lamellar/QII phase boundary. Addition of
agents such as WALP-like transmembrane peptides that
lower TQ could therefore increase the tendency of the lipids
to form fusion pore structures (QII phase precursors) between
apposed membranes.
The transmembrane domains of proteins may facilitate
membrane fusion
The membrane-spanning domains of viral fusion proteins
appear to act by stabilizing nascent fusion pores at a post-
hemifusion stage (see, e.g., Kemble et al. (72), Chernomordik
et al. (73), Melikyan et al. (74), Razinkov et al. (75),
Markosyan et al. (76), Melikyan et al. (77), Armstrong et al.
(78), and Frolov et al. (79); for reviews, see Schroth-Diez
et al. (29) and Earp et al. (80)). Moreover, peptides corre-
sponding to the transmembrane domains of fusion-mediating
proteins have been shown to induce liposome fusion in the
absence of other peptides or proteins (30–33). The peptides
in these studies acted at a posthemifusion stage, consistent
with peptide action in stabilizing nascent fusion pores. In
addition, peptides corresponding to mutants with reduced
fusion activity in vivo were less active in stimulating fusion
than the wild-type sequences.
In agreement with these results, this work also indicates
that transmembrane peptides should increase the suscepti-
bility of the lipids of membranes to membrane fusion. The
peptides do so through an effect on the lipid phase behavior.
Changes in lipid-peptide composition that stabilize QII
phases relative to the La phase also stabilize fusion pores
(16). We have shown that transmembrane WALP peptides
substantially stabilize QII phases (lower TQ) at concentra-
tions of only 0.5 mol %, which is comparable to physio-
logical conditions. For example, the fusion-mediating protein
inﬂuenza hemagglutinin (HA) is present at a monomer
concentration of 1.5 mol %, with each monomer having a
single transmembrane domain (calculated using data from
(81)). Transmembrane domains, if they have effects simi-
lar to those of WALP peptides on TQ, could substantially
accelerate fusion pore formation in biomembranes by a direct
effect on the lipids. This is in addition to, or instead of, action
of the domains through interactions with other regions of the
fusion proteins. Our results indicate that domains that are
either substantially longer or shorter than the thickness of the
lipid bilayer should be especially effective (Table 1and Fig.
3). If the membrane-spanning domains of fusion proteins are
as effective as WALP19 in reducing TQ in DOPE-Me, it can
be shown that a local concentration 1.0 mol % of such
domains would lower the energy of fusion pores by;40 kBT
(using data for DOPE-Me (16)).
The sequences of membrane-spanning domains affect
their fusion activity, both in full-length proteins in vivo and
in peptides in model membranes. For example, Langosch
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et al. (30,31), Hofman et al. (33), and Dennison et al. (32)
infer that facile interconversion between a-helical and
b-sheet structure is important for optimal fusion activity.
It would be interesting to test the effects of different fusion
protein membrane-spanning domains on TQ. This would
permit us to infer what (if any) role the QII-phase stabilizing
effect plays in activity of these domains, and whether the
observed differences in activity among domains of different
sequences is due to differences in the degree of QII phase
stabilization, or to other effects, such as changes in inter-
actions with other domains of the fusion proteins, or differ-
ences in the ability to stabilize hydrophobic interstices.
How much do the transmembrane domains of fusion proteins
resemble WALP peptides?
The transmembrane domain of at least one fusion protein,
inﬂuenza HA, has some features in common with the WALP
peptides. The HA membrane-spanning domain has inter-
facial anchoring groups similar to those in WALP peptides,
although fewer in number. In 18 strains of inﬂuenza virus, all
had at least one aromatic amino acid residue in a six-residue-
wide band at the N-terminal end of the domain (seven strains
had two), and 16 had either a tryptophan or phenylalanine
group at a single conserved location at the C-terminal end
(40). The aromatic residues in these sequences could act as
interfacial anchors (82), as do pairs of tryptophan residues in
the WALP peptides (5). The length of the sequence between
and including the inferred interfacial anchors in the HA
transmembrane domains is ;19–21 residues, as in a WALP
peptide with a total length of 23–25 residues. WALP23 has
a substantial effect on TQ (15C/mol %) of DOPE-Me
(Figs. 2 B and 3). Thus, it is possible that the transmem-
brane domain of HA exerts an inﬂuence on TQ in biomem-
branes that is analogous to the effect of WALP peptides in
DOPE-Me.
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